Interventions of Interest
- ensifentrine (Ohtuvayre, Verona Pharma)
An independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone. ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 to $12,700 per year, and the therapy is priced at $35,400 per year
Final Documents
ICER’s Chief Medical Officer David Rind, MD stated:
“COPD is a common cause of severe respiratory problems. Current evidence shows that ensifentrine decreases COPD exacerbations when used in combination with some current inhaled therapies, but there are uncertainties about how much benefit it may add to unstudied combinations of inhaled treatments. Unfortunately, the manufacturer chose a price for ensifentrine far above the value-based price. This may lead payers to implement formulary hurdles that could limit provider and patient access to this promising new treatment.”
For questions or to request a Spanish translated Report-at-a-Glance for this assessment, please contact info@icer.org.
View the Key Stakeholder List.
Public Comments
Closed